Last updated June 26th 2017
June 22, 2017 | Israeli biomed company Gamida Cell has raised $40 million in a financing round led by Israeli venture capital firm Shavit Capital. Also participating in this round were VMS Investment Group, Israeli Biotech Fund, Novartis, Clal Biotechnology Industries (CBI) and Israel HealthCare Ventures (IHCV). Through this new support, Gamida will be able to push the commercialization of its flagship product NiCord, which facilitates in-bone marrow transplants. Founded in 1998 by Tony Peled, the company has so far raised $90 million.